|
[1]
|
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42:3599-3726. |
|
[2]
|
Dai H, Lotan D, Much AA, et al. Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990-2017[J]. Front Cardiovasc Med, 2021, 8:610989. |
|
[3]
|
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J].Lancet, 2015, 386:743-800. |
|
[4]
|
Heymans S, Eriksson U, Lehtonen J, et al.The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy[J]. J Am Coll Cardiol, 2016, 68:2348-2364. |
|
[5]
|
Merken J, Hazebroek M, Van Paassen P, et al. Immunosuppressive Therapy Improves Both Shortand Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy[J]. Circ Heart Fail, 2018, 11:e004228. |
|
[6]
|
Das M, MR Bristow, MK Chung, The Essential Vulnerability of Human Cardiac Myocytes to SARSCoV-2[J]. JACC Basic Transl Sci, 2021, 6(4):346-349. |
|
[7]
|
Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis:predictors of mortality and incomplete recovery[J]. J Am Coll Cardiol, 2012, 59:1604-1615. |
|
[8]
|
Yeung C, Baranchuk A. Diagnosis and Treatment of Lyme Carditis:JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2019, 74:717-726. |
|
[9]
|
Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitorassociated myocarditis[J]. Lancet, 2018, 391:933. |
|
[10]
|
Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune Checkpoint Inhibitor Myocarditis:Pathophysiological Characteristics, Diagnosis, and Treatment[J]. J Am Heart Assoc, 2020, 9:e013757. |
|
[11]
|
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].Eur Heart J, 2013, 34:2636-2648, 2648a- 2648d. |
|
[12]
|
Staudt A, Schäper F, Stangl V, Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution[J]. Circulation, 2001, 103:2681-6. |
|
[13]
|
Ammirati E, Cipriani M, Lilliu M, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis[J].Circulation, 2017, 136:529-545. |
|
[14]
|
Gannon MP, Schaub E, Grines CL, et al. State of the art:Evaluation and prognostication of myocarditis using cardiac MRI[J]. J Magn Reson Imaging, 2019, 49:e122-e131. |
|
[15]
|
Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J]. N Engl J Med, 2000, 342:1077-1084. |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
